Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Company Overview - Genmab A/S is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics [2][3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3] Financial Reporting - Genmab filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. SEC, which includes parts of the Genmab A/S Annual Report 2024 [1] Strategic Vision - By 2030, Genmab aims to transform the lives of individuals with cancer and other serious diseases through its advanced antibody medicines, referred to as "knock-your-socks-off" (KYSO) therapies [2]